Filing Details

Accession Number:
0000899243-18-013572
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-05-21 16:36:25
Reporting Period:
2018-05-17
Accepted Time:
2018-05-21 16:36:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1629137 Global Blood Therapeutics Inc. GBT Pharmaceutical Preparations (2834) 274825712
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1650126 Jung Choi C/O Global Blood Therapeutics, Inc.
171 Oyster Point Blvd., Suite 300
South San Francisco CA 94080
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-05-17 1,600 $48.25 136,077 No 4 S Direct
Common Stock Acquisiton 2018-05-17 198 $3.40 136,275 No 4 M Direct
Common Stock Acquisiton 2018-05-17 601 $3.40 136,876 No 4 M Direct
Common Stock Acquisiton 2018-05-17 601 $3.40 137,477 No 4 M Direct
Common Stock Disposition 2018-05-17 1,400 $48.25 136,077 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2018-05-17 198 $0.00 198 $3.40
Common Stock Stock Option (Right to Buy) Disposition 2018-05-17 601 $0.00 601 $3.40
Common Stock Stock Option (Right to Buy) Disposition 2018-05-17 601 $0.00 601 $3.40
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
74,964 2025-04-08 No 4 M Direct
2,675 2025-04-08 No 4 M Direct
2,675 2025-04-08 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 25,000 Indirect By Trust
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  2. These shares of Common Stock were subject to the Issuer's right of repurchase, which lapsed with respect to 25% of the shares on April 6, 2016 and in 12 equal quarterly installments thereafter.
  3. 25% of the shares subject to this option vested and became exercisable on April 6, 2016 and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter.
  4. On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On March 10, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option.
  5. On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On September 29, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option.